Apellis Current Deferred Revenue from 2010 to 2024
| APLS Stock | USD 34.14 1.51 4.63% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 92.9 M | Current Value 86.1 M | Quarterly Volatility 8.1 M |
Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 31.1 M or Selling General Administrative of 525.9 M, as well as many indicators such as Price To Sales Ratio of 33.56, Dividend Yield of 0.0 or PTB Ratio of 19.3. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
Apellis | Current Deferred Revenue |
Latest Apellis Pharmaceuticals' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Apellis Pharmaceuticals over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Apellis Pharmaceuticals' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apellis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Apellis Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 107,783,180 | |
| Geometric Mean | 107,469,008 | |
| Coefficient Of Variation | 7.54 | |
| Mean Deviation | 6,089,336 | |
| Median | 111,935,000 | |
| Standard Deviation | 8,121,630 | |
| Sample Variance | 66T | |
| Range | 25.9M | |
| R-Value | (0.73) | |
| Mean Square Error | 32.7T | |
| R-Squared | 0.54 | |
| Significance | 0 | |
| Slope | (1,333,719) | |
| Total Sum of Squares | 923.5T |
Apellis Current Deferred Revenue History
About Apellis Pharmaceuticals Financial Statements
Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 92.9 M | 86.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.